The company will however, not be advancing the twice-daily formulation of danuglipron into Phase III studies.
Despite violations at 15 out of 39 sites involved in the study, BioVie reported positive data from its trial investigating NE3107.
The health authority has given the go-ahead for Part 1c of the PRO-101 trial investigating the use of prosetin in participants with ALS.
As per recommendations, Bayer will continue to investigate asundexian in a different Phase III trial with stroke patients.
The randomised trial was launched in 2017.
Give your business an edge with our leading industry insights.
A study published by the University of Ottawa found that the majority of Canada-based trials do not meet all reporting requirements.
The UK’s Autumn 2023 Statement takes a special interest in revitalising parts of the life sciences scene.
The data from the Phase II trial showed more than a 5% drop in weight in 57.1% of type 2 diabetes patients treated with 6mg of mazdutide.
The new scheme will launch in 2024 and aims to save the National Health Service (NHS) £14bn over five years.
The report published by the Association of the British Pharmaceutical Industry found that UK trials rose from 394 in 2021 to 411 in 2022.